Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Rating of “Hold” by Analysts

Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONSGet Rating) have earned an average rating of “Hold” from the twelve analysts that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $41.78.

A number of equities analysts recently weighed in on IONS shares. SVB Leerink lowered their price objective on shares of Ionis Pharmaceuticals from $29.00 to $26.00 and set a “market perform” rating on the stock in a research report on Friday, April 1st. TheStreet upgraded shares of Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Wednesday, April 20th. Bank of America lowered shares of Ionis Pharmaceuticals from a “buy” rating to an “underperform” rating and decreased their target price for the stock from $40.00 to $30.00 in a research report on Tuesday, February 1st. Guggenheim initiated coverage on shares of Ionis Pharmaceuticals in a research report on Tuesday, March 1st. They set a “buy” rating and a $64.00 target price on the stock. Finally, StockNews.com upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday.

Shares of Ionis Pharmaceuticals stock opened at $36.30 on Monday. The firm’s fifty day simple moving average is $37.22 and its 200-day simple moving average is $33.44. The stock has a market capitalization of $5.15 billion, a price-to-earnings ratio of -181.49 and a beta of 0.78. Ionis Pharmaceuticals has a 12 month low of $25.04 and a 12 month high of $44.42. The company has a debt-to-equity ratio of 1.76, a current ratio of 9.86 and a quick ratio of 9.65.

Ionis Pharmaceuticals (NASDAQ:IONSGet Rating) last announced its earnings results on Wednesday, May 4th. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.22. Ionis Pharmaceuticals had a negative net margin of 0.36% and a negative return on equity of 0.46%. The business had revenue of $142.00 million for the quarter, compared to analysts’ expectations of $122.46 million. During the same period in the previous year, the company posted ($0.64) EPS. The company’s quarterly revenue was up 26.8% on a year-over-year basis. Analysts anticipate that Ionis Pharmaceuticals will post -2.41 earnings per share for the current year.

In other news, EVP Patrick R. O’neil sold 6,792 shares of the company’s stock in a transaction dated Tuesday, April 12th. The shares were sold at an average price of $40.06, for a total transaction of $272,087.52. Following the completion of the transaction, the executive vice president now owns 34,536 shares of the company’s stock, valued at approximately $1,383,512.16. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders sold a total of 7,525 shares of company stock valued at $302,085 in the last three months. 2.96% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. National Bank of Canada FI purchased a new stake in shares of Ionis Pharmaceuticals during the 4th quarter worth about $2,130,000. Baillie Gifford & Co. grew its holdings in shares of Ionis Pharmaceuticals by 4.6% during the 4th quarter. Baillie Gifford & Co. now owns 315,820 shares of the company’s stock worth $9,611,000 after purchasing an additional 13,817 shares during the period. Janney Montgomery Scott LLC grew its holdings in shares of Ionis Pharmaceuticals by 6.6% during the 4th quarter. Janney Montgomery Scott LLC now owns 36,424 shares of the company’s stock worth $1,108,000 after purchasing an additional 2,271 shares during the period. Captrust Financial Advisors grew its holdings in shares of Ionis Pharmaceuticals by 30.4% during the 3rd quarter. Captrust Financial Advisors now owns 2,472 shares of the company’s stock worth $83,000 after purchasing an additional 576 shares during the period. Finally, State of New Jersey Common Pension Fund D grew its holdings in shares of Ionis Pharmaceuticals by 9.2% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 95,234 shares of the company’s stock worth $2,898,000 after purchasing an additional 8,018 shares during the period. 95.16% of the stock is owned by institutional investors.

About Ionis Pharmaceuticals (Get Rating)

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy.

See Also

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.